Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 29 of 99 for:    Oleic Acids

PK and PD of Sequential Multiple Ascending, Repeat Doses of Oral CXA-10 in Healthy Obese Male Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02460146
Recruitment Status : Completed
First Posted : June 2, 2015
Last Update Posted : May 3, 2016
Sponsor:
Information provided by (Responsible Party):
Complexa, Inc.

Brief Summary:
The main purpose of this trial is to demonstrate the safety, tolerability and pharmacokinetics (PK) of CXA-10 and its metabolite(s) administered as multiple ascending oral doses over 14 days to healthy obese male volunteers.

Condition or disease Intervention/treatment Phase
Acute Kidney Injury Drug: CXA-10 Other: CXA-10 placebo Phase 1

Detailed Description:
Complexa has developed an oral formulation of CXA-10. The main purpose of this trial is to demonstrate the safety, tolerability and pharmacokinetics (PK) of CXA-10 and its metabolite(s) administered as multiple ascending oral doses over 14 days to healthy obese male volunteers. The pharmacodynamic (PD) effects of CXA-10 on serum biomarkers, some of which are elevated in the obese population, will also be investigated.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 43 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Sequential Multiple Ascending, Repeat Doses of Oral CXA-10 in Healthy Obese Male Subjects
Study Start Date : April 2015
Actual Primary Completion Date : September 2015
Actual Study Completion Date : October 2015

Arm Intervention/treatment
Active Comparator: CXA-10
CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
Drug: CXA-10
CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid

Placebo Comparator: CXA-10 placebo
The placebo contains olive oil with BHT (0.08% to 0.10%).
Other: CXA-10 placebo
The placebo contains olive oil with BHT (0.08% to 0.10%).




Primary Outcome Measures :
  1. Safety (adverse events) and tolerability of multiple ascending oral doses of CXA 10 administered daily for 14 days [ Time Frame: 14 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Body mass index (BMI) >27 and ≤40 kg/m2
  • In good general health as determined by a thorough medical history and physical examination, ECG, vital signs, and clinical laboratory evaluation
  • Results of clinical laboratory tests must be without clinically significant abnormalities for this population and may exceed the limits of the reference ranges, including hematology, clinical chemistry and urinalysis except as noted below
  • Hemoglobin A1c (HbA1c) <7%
  • Average blood pressure <160/100 mmHg at screening
  • QTcF interval (Fredericia's correction factor) must be ≤430 msec at screening and pre-dose

Exclusion Criteria:

  • Any clinically relevant abnormality for this population identified on the screening history, physical or laboratory examinations, or any other medical condition or circumstance making the volunteer unsuitable for participation in the study
  • Any clinical history of cardiovascular events, arrhythmias, fainting, palpitations, personal or family history of congenital prolonged QT syndromes or sudden unexpected death due to a cardiac reason
  • History of any primary malignancy, including a history of melanoma or suspicious undiagnosed skin lesions, with the exception of basal cell or squamous cell carcinomas of the skin or cervical carcinoma in situ or other malignancies curatively treated and with no evidence of disease for at least 5 years
  • History of regular alcohol consumption exceeding 21 units/week (one unit = 125 mL of wine or 284 mL of beer or a single 25 mL measure of spirits) within 6 months of screening
  • Treatment with any prescription or non-prescription drugs (including vitamins, herbal and dietary supplements) within 7 days or 5 half-lives, whichever is longer, prior to dosing and until collection of the final PK sample. Use of any drug including aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) must be avoided within 7 days prior to the first dose and during this study as it may interfere with the pharmacology of CXA-10. Use of high energy supplements or drinks (especially, those containing caffeine, protein supplements, and weight loss drugs)
  • History of smoking, including e-cigarettes, or use of nicotine-containing products within 1 month of screening
  • Resting heart rate ≥100 BPM after 5 minutes rest (as above) at the screening visit
  • Subjects with any other clinically relevant ECG parameter abnormality (e.g., PR interval, QRS deviation) or any clinically significant ECG abnormality will be excluded from the study
  • Any clinically significant murmurs evident on auscultation of the heart (including evidence of mitral valve prolapse)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02460146


Locations
Layout table for location information
United States, Michigan
Jasper Clinical Research & Development, Inc.
Kalamazoo, Michigan, United States, 49007
Sponsors and Collaborators
Complexa, Inc.
Investigators
Layout table for investigator information
Principal Investigator: Thomas Blok, MD Jasper Clinic, Michigan

Layout table for additonal information
Responsible Party: Complexa, Inc.
ClinicalTrials.gov Identifier: NCT02460146     History of Changes
Other Study ID Numbers: CXA-10-202
First Posted: June 2, 2015    Key Record Dates
Last Update Posted: May 3, 2016
Last Verified: May 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Acute Kidney Injury
Renal Insufficiency
Kidney Diseases
Urologic Diseases